Business
Patrick Collison
Stripe cofounder Patrick Collison (Manuel Blondeau/Getty Images)
Weird Money

Stripe keeps bending over backward to stay private and still let employees get rich

Big Stripe investor Sequoia turned to its own funds to provide liquidity for some of the longest-tenured Stripe shareholders.

Jack Raines

A few weeks ago, I wrote about Stripe’s continued refusal to go public, mentioning that one issue with remaining private is that many of your long-time employees will, eventually, want to sell some of their shares and turn their paper millions into real millions. To quote myself:

In 2021, Stripe was the hottest startup in tech. In March of that year, it raised $600 million at a $95 billion valuation, and six months later, the company was flirting with the idea of going public. Three years later, Stripe still hasn’t gone public, and its valuation (as of February 2024) has declined to $65 billion. If you’re a long-time employee still holding your paper shares, you can’t be too happy about missing the liquidity event of a lifetime.

So Stripe devised a solution: because outside demand for stakes in the company was so high, Stripe could facilitate tender offers allowing some of its employees to sell their shares to outside investors. From Bloomberg:

Stripe Inc. expects to again let employees cash out some of their shares, the fintech’s co-founder said, reiterating that the company is in no rush for an initial public offering.

Stripe, which helps online and brick-and-mortar merchants process customer payments, will probably again turn to investors and the firm’s own coffers for an employee tender offer — which would be its third, John Collison said in an interview with David Rubenstein.

‘We did that last year, we did that this year, and we’ll probably do it again in the future,’ Collison said.

While venture capital subsidized Stripe’s ability to stay private by creating a medium for its employees to liquidate their shares through tender offers, one group of investors has still been waiting to sell its shares for more than a decade: the limited partners (LPs) in the VC funds that invested in Stripe’s earliest funding rounds.

That said, it appears that some of Sequoia Capital’s LPs from funds that invested in Stripe between 2009 and 2012 are going to receive an $861 million payday. The buyer? Sequoia’s newer funds. From Axios:

Sequoia this morning emailed LPs in funds raised between 2009 and 2012, offering to buy up to $861 million of Stripe shares. The purchasers would be other, more recent Sequoia Capital funds — a process partially enabled by the firm's 2021 restructuring.

The price would be $27.51 per share, which is Stripe's most recent 409A mark and represents a $70 billion valuation. For context, Stripe was valued at $95 billion back in 2021, but by last summer had slashed its worth to $50 billion…

Sequoia is recognizing what some of its investors need, while simultaneously expressing faith in Stripe's future. What's not clear, however, is why Sequoia is convinced that Stripe will enable an exit that rewards such faith. Internal messaging has been to expect an IPO eventually, but its actions have suggested that the founding Collison brothers would rather stay private indefinitely.

Sequoia invested in Stripe’s 2012 Series B at a valuation of “hundreds of millions” of dollars, and Stripe is now worth $70 billion, meaning that, ignoring further dilution, LPs from the 2012 investment are sitting on at least a 100x return. Those LPs would like to realize that return, but Stripe’s founders have no intention of taking the company public any time soon.

If you are Sequoia, what do you do?

Well, investor demand has remained high for Stripe shares, considering the company hasn’t had a problem finding investors to purchase employees’ shares in secondary offerings, and Stripe is still growing quickly, with Axios noting that the fintech giant handled $1 trillion in payment volume in 2023, up 25% from 2022, so I doubt LPs in Sequoia’s new funds will question a Stripe investment. Moving shares from an older Sequoia fund to newer Sequoia funds is a short-term option that resets the timeline by which Sequoia will need to distribute capital from its Stripe investment to its LPs.

But sooner or later, I imagine Sequoia (and other VC firms) will want to sell their stakes, right? The venture model is predicated on buying stakes in private startups to fund their growth, with the expectation that you’ll realize gains from an acquisition or IPO. Moving your Stripe stake from fund to fund doesn’t benefit anyone except Stripe’s founders, who have expressed that they have no desire to go public.

In February, Axios noted that “Stripe had told employees to expect annual opportunities to sell shares,” and those opportunities can only stem from one of two sources: outside investors buying shares in secondary offerings, or the company itself buying shares back. At some point, you would think that venture capitalists would grow tired of subsidizing Stripe’s life as a private company, stop offering to buy employees’ shares, and pressure management to take the company public.

But until then, I guess Sequoia will keep selling to Sequoia.

More Business

See all Business
business

Hims to stop offering copy of Wegovy pill following FDA scrutiny

Hims & Hers said it has decided to stop offering its newly launched copycat version of Novo Nordisk’s Wegovy pill, after the telehealth company drew criticism from the Food and Drug Administration. 

“Since launching the compounded semaglutide pill on our platform, we’ve had constructive conversations with stakeholders across the industry. As a result, we have decided to stop offering access to this treatment,” Hims wrote on X.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Shares of Hims are down double digits in premarket trading on Monday, while Novo Nordisk ADRs are up more than 6% as of 5:20 a.m. ET.

On Friday afternoon, the FDA said it would take “decisive steps” to restrict GLP-1 compounding. Department of Health and Human Services General Counsel Mike Stuart said on social media Friday he had referred Hims to the Department of Justice “for investigation for potential violations by Hims of the Federal Food, Drug, and Cosmetic Act and applicable Title 18 provisions.”

Hims launched the product last week, a seeming copy of a recently released and patented drug, which immediately drew fire from Novo Nordisk and regulators.

Hims oral semaglutide

Hims, long flying under regulators’ radar, finally strikes a nerve with its Wegovy pill copy

It’s unclear if the pill Hims is selling works or if the FDA will allow it.

$1.3M

There’s still plenty of money to be made in brainrot. The top 1,000 Roblox creators earned an average of $1.3 million in 2025 — up 50% from the year prior — according to CEO Dave Baszucki on the company’s fourth-quarter earnings call.

Roblox paid out $1.5 billion to creators last year, meaning its top 1,000 creators took home about 87% of the total pool.

Like other creator economy giants, Roblox rewards its biggest creators for their contributions to user engagement. Creator-made titles like “Grow a Garden” and “Steal a Brainrot” substantially boosted playing time over the course of the year. In September, the company increased its developer exchange rate, or the ratio of in-game currency to cash payout, by 8.5%.

Texas Governor Abbott And Google Make Economic Development Announcement In Midlothian

Alphabet could buy some pretty huge businesses with the amount of money it plans to spend this year

AI outlays have gone full nut-nut. Even Google, one of the most capital-efficient businesses of all time in its heyday, is spending like there’s no tomorrow.

Tom Jones2/6/26

Latest Stories

Sherwood Media, LLC produces fresh and unique perspectives on topical financial news and is a fully owned subsidiary of Robinhood Markets, Inc., and any views expressed here do not necessarily reflect the views of any other Robinhood affiliate, including Robinhood Markets, Inc., Robinhood Financial LLC, Robinhood Securities, LLC, Robinhood Crypto, LLC, or Robinhood Money, LLC.